G1043
Guanfacine hydrochloride
≥98% (HPLC)
Synonym(s):
N (Aminoiminomethyl)-2,6-dichlorobenzeneacetamide
Sign Into View Organizational & Contract Pricing
Select a Size
About This Item
Empirical Formula (Hill Notation):
C9H9Cl2N3O · HCl
CAS Number:
Molecular Weight:
282.55
MDL number:
UNSPSC Code:
12352200
PubChem Substance ID:
NACRES:
NA.77
Assay
≥98% (HPLC)
color
white
solubility
H2O: soluble 12 mg/mL at 60 °C
originator
Promius
SMILES string
Cl.NC(=N)NC(=O)Cc1c(Cl)cccc1Cl
InChI
1S/C9H9Cl2N3O.ClH/c10-6-2-1-3-7(11)5(6)4-8(15)14-9(12)13;/h1-3H,4H2,(H4,12,13,14,15);1H
InChI key
DGFYECXYGUIODH-UHFFFAOYSA-N
Gene Information
human ... ADRA2A(150), ADRA2B(151), ADRA2C(152)
Looking for similar products? Visit Product Comparison Guide
Related Categories
Application
Guanfacine hydrochloride has been used as an α2A adrenoceptor agonist to test its protective effect on hypobaric hypoxia (HH) and in rat brain to measure blood oxygenation level dependent (BOLD) response.
Biochem/physiol Actions
α-2 noradrenergic receptor agonist.
Guanfacine stimulates the brain postsynaptic α2 adrenergic receptor (AR) and mediates the prefrontal cortical (PFC) neuronal regulation and strengthens their network. Guanfacine improves the density of neuronal dendrites and is useful in treating neuropsychiatric disorders. It modulates the synaptic and cytoskeletal proteins expression in prefrontal cortical (PFC) neurons and may improve hypobaric hypoxia (HH) induced PFC dysfunctions. Guanfacine enhances cognitive function and is recommended for attention deficit hyperactivity disorder (ADHD) therapy.
Features and Benefits
This compound was developed by Promius. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
Storage Class Code
11 - Combustible Solids
WGK
WGK 3
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Personal Protective Equipment
dust mask type N95 (US), Eyeshields, Gloves
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Yuanyuan Li et al.
Rapid communications in mass spectrometry : RCM, 26(10), 1208-1212 (2012-04-14)
A two-layered polymeric membrane is employed for the formation of separated dried plasma spots from whole blood as an alternative to the direct analysis of whole dried blood spots (DBS). This dried plasma spot (DPS) analysis procedure precludes potential issues
James Signorovitch et al.
Pharmacoepidemiology and drug safety, 21 Suppl 2, 130-137 (2012-05-11)
To illustrate a matching-adjusted indirect comparison by comparing the efficacy of guanfacine extended release (GXR) and atomoxetine (ATX) in reducing oppositional symptoms in children with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder. Individual patient data were used from a GXR
Guanfacine ameliorates hypobaric hypoxia induced spatial working memory deficits
Kauser H, et al.
Physiology & Behavior, 123, 187-192 (2014)
Katharine Pillidge et al.
British journal of pharmacology, 171(20), 4785-4796 (2014-07-31)
Mice with functional ablation of substance P-preferring neurokinin-1 receptors (NK1R-/- mice) display behavioural abnormalities resembling those in attention deficit hyperactivity disorder (ADHD). Here, we investigated whether the ADHD treatment, guanfacine, alleviated the hyperactivity and impulsivity/inattention displayed by NK1R-/- mice in
Floyd R Sallee et al.
Journal of child and adolescent psychopharmacology, 22(3), 206-214 (2012-05-23)
Extended-release guanfacine (GXR) is approved for the treatment of attention-deficit/hyperactivity disorder (ADHD) in children and adolescents aged 6-17 years. This post-hoc analysis further examines the effects of GXR on hyperactivity-impulsivity and inattentiveness. Data from two large double-blind placebo-controlled pivotal trials
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service